Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated, commercial-stage biopharmaceutical company, has announced that it will deliver an oral presentation on its investigational TNX-801 vaccine platform and lead a working group session at the World Vaccine Congress Europe, scheduled for October 19-21, 2026, in Amsterdam, Netherlands. The presentation, set for October 21 at 1:15 p.m. CEST, will address the safety and efficacy of TNX-801, a live, attenuated, minimally replicative horsepox virus-based vaccine platform being developed to protect against mpox and other infectious diseases. Tonix will also lead a working group session titled “Vectored Vaccine Platforms: From Design to Improving Efficacy” on October 20 at 11:30 a.m. CEST.
The World Vaccine Congress Europe is a significant forum for vaccine research and development, bringing together experts from industry, academia, and government. Tonix's participation underscores the company's commitment to advancing immunology programs and addressing unmet medical needs. The TNX-801 platform, based on horsepox virus, is designed to be minimally replicative, which may offer safety advantages over traditional live vaccines. If successful, TNX-801 could provide a new tool against mpox, a disease that has seen outbreaks in recent years and remains a global health concern.
Tonix is a fully integrated commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. Its recently approved flagship medicine, TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), is the first new treatment for fibromyalgia in more than 15 years. The company's CNS commercial infrastructure supports its marketed products, including acute migraine products Zembrace® SymTouch® and Tosymra®. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. For more details on Tonix's pipeline and updates, visit its newsroom at https://ibn.fm/TNXP.
The announcement is important for investors and the biotech industry as it highlights Tonix's progress in immunology and its potential to contribute to global health. The World Vaccine Congress Europe provides a platform for Tonix to showcase its science and engage with key stakeholders, which could lead to partnerships and accelerate development. For readers, this news signifies ongoing innovation in vaccine technology that may eventually lead to new options for preventing infectious diseases.
BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences, is one of 75+ brands within the Dynamic Brand Portfolio @ IBN. The platform delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics, and diverse industries. It also offers article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. For more information, visit BioMedWire.
